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ABSTRACT
Introduction: The aim of the study was to evaluate the contribution of genetic variants determining inherited throm-
bophilia to recurrent miscarriage (RM) in the Polish population. The following polymorphisms were analyzed: 1691G>A, 
1328T>C of coagulation factor V, 20210G>A of coagulation factor II, R353Q (11496G>A) of coagulation factor VII, 667C>T, 
1298A>C, 1793G>A of MTHFR.
Material and methods: A total of 359 women with ≥ 2 subsequent recurrent miscarriages (303 < 13 weeks of gestation 
(w.g.) and 56 between 13–22 w.g.) and 400 healthy controls were included in the study. Frequency of the genetic polymor-
phisms was determined with the PCR/RFLP method.
Results: Higher frequency of the 20210GA genotype was found in the RM < 13 w.g. (2.97 vs. 1.50% in controls, OR = 2.01, ns) 
and the RM 13–22 w.g. (5.36 vs. 1.50% in controls, OR = 3.72, p = 0.09) subgroups. Statistically significantly higher frequency 
of the 11496GA genotype was noted in controls as compared to the RM 13–22 w.g. subgroup (10.71 vs. 23.00% in controls, 
OR = 0.40, p = 0.02). Statistically significantly higher frequency of the 1793GA genotype was observed in the RM < 13 w.g. 
subgroup as compared to controls (12.21 vs. 7.75% in controls, OR = 1.66, p = 0.03). No significant correlations were found 
as far as the rest of the analyzed polymorphisms are concerned.
Conclusions: The obtained results suggest that the 1793G>A MTHFR, R353Q (11496G>A) factor VII gene and the 20210G>A fac-
tor II gene polymorphisms play a role in the etiology of RM in the Polish population.
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INTRODUCTION
Polymorphic variants of genes involved in the coagu-
lation cascade and fibrinolysis are believed to play a key 
role in the etiology of recurrent miscarriage (RM). Inher-
ited thrombophilia may result in significant changes in the 
utero-placental circulation, including placental infarction, 
atherosclerotic changes in vessels, and placental insuffi-
ciency [1–4].
The most common causes of inherited thrombophilia 
are polymorphisms in genes encoding factor V, prothrombin 
(factor II), factor VII, methylenetetrahydrofolate reductase 
(MTHFR), and plasminogen activator inhibitor, while protein C, 
protein S and antithrombin deficiency is less common. Stud-
ies confirming a correlation between inherited thrombophilia 
and recurrent pregnancy loss have been performed all over 
the world and concerned diverse ethnic populations [5–7].
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One of a number of hypotheses concerning a correla-
tion between inherited thrombophilia and RM is based on 
the fact that coagulation cascade stimulation caused by 
endothelial dysfunction is more likely to occur in women 
with genetic defects of hemostatic factors predisposing 
to thrombotic changes in the placental circulation [8, 9]. 
The subsequent complications, especially miscarriage, are 
probably conditioned by impaired placental development 
and improper placental perfusion. Thrombotic tendency 
may be manifested by the so-called ‘thrombotic damage 
of placental circulation’. Those changes are known as the 
‘pregnancy vascular complications’ [10, 11].
Pregnancy itself is a condition which favors the appear-
ance of physiological hypercoagulability and, with the ad-
ditional presence of genetic defects of coagulation cascade 
and fibrinolysis, which may result in serious obstetrical com-
plications, including RM [12, 13].
The fact that pregnancy-related complications develop 
only in some carriers of thrombotic mutations remains 
a source of much controversy, although environmental fac-
tors have been mentioned as the possible cause. Numerous 
maternal hemostatic proteins cooperate with trophoblas-
tic coagulation cascade components. That process is es-
sential for proper embryogenesis. Coagulation proteins 
are believed to act also as regulatory and signal factors 
in immunological reactions and cellular proliferation, al-
though further studies are necessary to fully elucidate the 
matter [14, 15].
OBJECTIVES
The goal of the research was to evaluate the contribu-
tion of genetic variants determining inherited thrombo-
philia to recurrent miscarriage (RM) in the Polish population. 
The following polymorphisms were analyzed: 1691G>A, 
1328T>C of coagulation factor V, 20210G>A of coagulation 
factor II, R353Q (11496G>A) of coagulation factor VII, 667C>T, 
1793G>A and 1298A>C of MTHFR. 
MATERIAL AND METHODS
A total of 359 women with ≥ 2 RM and 400 healthy con-
trols were included in the study. Miscarriage was defined as 
the ‘loss of pregnancy before 22 completed weeks of gesta-
tion (w.g.)’. Gestational age at the time of miscarriage was 
calculated according to the date of the last menstruation 
and ultrasound evaluation. All subjects were Caucasian and 
of Polish origin nationality. The patients were enrolled at the 
Division of Perinatology and Women’s Diseases, Poznan Uni-
versity of Medical Sciences. The study was performed be-
tween 2009 and 2015. Local Ethics Committee approved 
of the study (1082/07, 867/15, 210/16). All patients gave 
their written informed consent. All participants were taking 
400 mg folic acid per day at the time of the study. 
Study group
The study group was divided into two subgroups: 
303 women with ≥ 2 subsequent RM < 13 w.g. during one 
relationship and 56 women with ≥ 2 subsequent RM be-
tween 13–22 w.g. during one relationship. The presence of 
protein C, protein S, antithrombin deficiency as well as an-
tiphospholipid syndrome were excluded in all subjects. Each 
patient had a negative history of thrombotic events. Patients 
with known reasons for RM (e.g. anatomical anomalies of 
the genitourinary tract, chromosomal aberrations, acquired 
thrombophilia, chronic diseases, infections, hormonal dis-
turbances), cervical insufficiency, or other obstetric com-
plications which could be a cause of RM (e.g. hypertension 
diagnosed in the course of pregnancy, gestational diabetes 
mellitus, anatomical and genetic fetal defects, serological 
conflict) were excluded. Only patients with RM of an un-
known origin were included into the analysis.
Control group
The control group included 400 healthy women with 
a medical history of at least two uncomplicated pregnancies 
ended at term with a delivery of a healthy infant. No mis-
carriages were recorded in this group. All women positive 
for miscarriage, other obstetric complications caused by 
thrombotic changes chronic diseases, acquired thrombo-
philia (antiphospholipid syndrome), and positive history of 
thrombotic events were excluded from the analysis. Gesta-
tional age at the time of delivery was calculated according to 
the date of the last menstruation and ultrasound evaluation.
Clinical characteristics of the study population are pre-
sented in Table 1. 
Genetic analysis
DNA was isolated from blood leucocytes using QIAamp 
DNA Blood Mini Kit (QIAGEN Inc., Germany). The frequency 
of the investigated genetic polymorphisms was assessed by 
polymerase chain reaction (PCR) and restriction fragment 
length polymorphism (RFLP). Genetic analysis was per-
formed at the Laboratory of Molecular Biology, Division of 
Perinatology and Women’s Diseases, PUMS. Table 2 presents 
used primers. Investigated polymorphisms were recognized 
by adequate restriction enzyme hydrolysis. Hydrolyzed PCR 
products were analyzed on a 2% agarose gel. Visualization 
was performed under UV light.
Statistical methods
Statistical analyses were performed using SPSS22.0 PL 
for Windows. The p-value of < 0.05 was considered as statisti-
cally significant. Genotype frequencies were compared by 
chi-square test (one-sided Fisher test). The expected geno-
type frequencies were calculated from allele frequencies 
with the use of the Hardy-Weinberg equation. 
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RESULTS
There were no statistically significant correlations for 
the 1691G>A factor V gene polymorphism in both study 
subgroups and controls. The frequency of the heterozygous 
1691GA genotype was comparable in all analyzed groups 
(7.59% in the RM < 13 w.g. subgroup, 5.36% in the RM 13– 
–22 w.g. subgroup and 5.25% in controls, ns). Also, the occur-
rence of the mutated 1691A allele was similar in all investi-
gated groups (3.80% in the RM < 13 w.g. subgroup, 2.68% in 
the RM 13–22 w.g. subgroup, 2.88% in controls, ns) (Table 3).
The analysis of the 1328T>C factor V gene polymorphism 
revealed comparable frequency of its variants. Congenial 
occurrence of heterozygous 1328TC and homozygous 
1328CC genotypes was observed in the RM < 13 w.g. sub-
group (23.76% and 1.65%), in the RM 13–22 w.g. subgroup 
(16.07% and 1.79%) and in controls (22.25% and 1.25%). As 
for the mutated 1328C allele, a similar frequency was also 
noted: 13.53% in the RM < 13 w.g. subgroup, 9.82% in the 
RM 13–22 w.g. subgroup, and 12.38% in controls (Table 4).
While analyzing the 20210G>A factor II gene polymor-
phism, higher frequency of the heterozygous 20210GA 
genotype was observed in the RM < 13 w.g. subgroup 
(2.97 vs. 1.50% in controls, OR = 2.01, ns) and in the RM 
13–22 w.g. subgroup (5.36 vs. 1.50% in controls, OR = 3.72, 
p = 0.09). The same correlation was found in the mutated 
20210A allele — its frequency was higher in the RM < 13 RM 
subgroup (1.49 vs. 0.75% in controls, OR = 1.99, ns) and in 
the RM 13-22 w.g. subgroup (2.68 vs. 0.75% in controls, 
WR = 3.72, p = 0.09) (Table 5).
Similar observations were made for the R353Q 
(11496G>A) factor VII gene polymorphism. Statistically sig-
nificantly higher frequency of the heterozygous 11496GA 
genotype was noted in controls as compared to the RM 
13–22 w.g. subgroup (10.71 vs. 23.00% in controls, OR = 0.40, 
p = 0.02). Comparable statistical differences concerned gen-
otypes containing the mutated 11496A allele (GA + AA) in 
the RM < 13 w.g. subgroup and in controls (12.50 vs. 24.50%, 
OR = 0.44, p = 0.029). The frequency of the mutated 11496A 
allele was also higher in controls as compared to the RM 
13–22 w.g. subgroup (7.14 vs. 13.00% in controls, OR = 0.51, 
p = 0.05) (Table 6).
Table 1. Clinical characteristics of the study and control groups.
RM (n = 359) Controls  
(n = 400)p
Age (years)
Mean + SD
Median
Min/max
 
30.99 ± 4.50
31.00
20.00–45.00
0.001
 
30.05 ± 3.81
30.00
22.00–44.00
Systolic [mm Hg]
Mean + SD
Median
Min/max
 
109.86 ± 12.63
110.00
80.00–140.00
0.08
 
111.36 ± 10.70
110.00
80.00–150.00
Diastolic [mm Hg]
Mean + SD
Median
Min/max
 
68.05 ± 10.11
70.00
50.00–100.00
0.0005
 
70.51 ± 9.24
70.00
50.00–95.00
Height [cm]
Mean + SD
Median
Min/max
 
165.89 ± 5.58
165.00
150.00–179.00
0.19
 
166.42 ± 5.44
166.00
155.00–180.00
Weight [kg]
Mean + SD
Median
Min/max
 
62.46 ± 9.25
62.00
43.00–92.00
0.002
 
59.83 ± 9.82
58.00
39.00–110.00
BMI [kg/m2]
Mean + SD
Median
Min/max
 
22.64 ± 3.25
21.97
17.19–36.85
0.0001
 
21.58 ± 3.26
20.72
16.02–38.57
Number of RM
1 miscarriage
2 RM
3 or more RM
 
0
282
77
–
 
0
0
0
Table 2. Primers used in genetic analysis
Gene Polymorphism Primer sequence References
MTHFR
677C>T 
(A222V) 
5’ TGA AGG AGA AGG TGT CTG CGG GA 3’
5’ AGG ACG GTG CGG TGA GAG TG 3’ Frost et al. 1995
1298A>C 
(E429A)
5’ CTT CTA CCT GAA GAG CAA GTC-3’
5’ CAT GTC CAC AGC ATG GAG-3’ Hanson et al. 2001
1793G>A 
(R594Q)
5’ CTC TGT GTG TGT GTG CAT GTG TGC G 3’ 
5’ GGG ACA GGA GTG GCT CCA ACG CAG G 3’ Rady et al. 2002
FV
1691G>A 
(R506Q)
5’ TGC CCA GTG CTT AAC AAG ACC A 3’ 
5’ CTT GAA GGA AAT GCC CCA TTA 3’ Bertina et al. 1994
1328T>C 
(M385T)
5’ ACA TAC AGT GAA TCC CAG TA 3’ 
5’ ATG AGC ATC TTT TTC TTT TA3’ Faisel et al. 2004
FII 20210G>A 5’ TCT AGA AAC AGT TGC CTG GC 3’ 5’ ATA GCA CTG GGA GCA TTG AAG C3’ Poort et al. 1996
FVII 10916G>A (R353Q)
5’ GGG AGA CTC CCC AAA TAT CAC 3’
5’ ACG CAG CCT TGG CTT TCT CTC 3’ Green et al. 1991
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Table 3. The frequency of genotypes and alleles of the 1691G>A factor V gene polymorphism in the study group and controls
FV
1691G>A
Study group RM (n = 359)
Control group (n = 400)
RM < 13 w.g. (n = 303) RM 13–22 w.g. (n = 56)
Genotypes
Observed 
value 
n (%)
Expected 
value 
(%)
OR p
Observed 
value
n (%)
Expected 
value
(%)
OR p
Observed 
value
n (%)
Expected 
value
(%)
1691GG 280 (92.41) 92.55 0.71 0.17 53 (94.64) 94.72 1.03 0.63 378 (94.50) 94.33
1691GA 23 (7.59) 7.30 1.48 0.13 3 (5.36) 5.21 1.02 0.58 21 (5.25) 5.59
1691AA 0 (0.00) 0.15 – – 0 (0.00) 0.07 – – 1 (0.25) 0.08
Total 303 (100.00) 100.00 56 (100.00) 100.00 400 (100.00) 100.00
Alleles
1691G 583 (96.20) – 0.75 0.21 109 (97.32) – 1.08 0.60 777 (97.12) –
1691A 23 (3.80) – 1.33 0.21 3 (2.68) – 0.93 0.60 23 (2.88) –
Total 606 (100.00) – 112 (100.00) – 800 (100.00) –
Study subgroups were compared to the control group; p — one-sided exact Fisher test
Table 4. The frequency of genotypes and alleles of the 1328T>C factor V gene polymorphism in the study group and controls
FV
1328T>C
(M385T)
Study group RM (n = 359)
Control group (n = 400)
RM < 13 w.g. (n = 303) RM 13–22 w.g. (n = 56)
Genotypes
Observed 
value
n (%)
Expected 
value 
(%)
OR p
Observed 
value
n (%)
Expected 
value
(%)
OR p
Observed 
value
n (%)
Expected 
value
(%)
1328TT 226 (74.59) 74.77 0.90 0.31 46 (82.14) 81.32 1.41 0.22 306 (76.50) 76.78
1328TC 72 (23.76) 23.40 1.09 0.35 9 (16.07) 17.71 0.67 0.19 89 (22.25) 21.69
1328CC 5 (1.65) 1.83 1.33 0.45 1 (1.79) 0.97 1.44 0.54 5 (1.25) 1.53
Total 303 (100.00) 100.00 56 (100.00) 100.00 400 (100.00) 100.00
Alleles
1328T 524 (86.47) – 0.90 0.29 101 (90.18) – 1.30 0.27 701 (87.62) –
1328C 82 (13.53) – 1.11 0.29 11 (9.82) – 0.77 0.27 99 (12.38) –
Total 606 (100.00) – 112 (100.00) – 800 (100.00) –
Study subgroups were compared to the control group; p — one-sided exact Fisher test
Table 5. The frequency of genotypes and alleles of the 20210G>A factor II gene polymorphism in the study group and controls
FII
20210G>A
Study group RM (n = 359)
Control group (n = 400)
RM < 13 w.g. (n = 303) RM 13–22 w.g. (n = 56)
Genotypes
Observed 
value
n (%)
Expected 
value 
(%)
OR p
Observed 
value
n (%)
Expected 
value 
(%)
OR p
Observed 
value
n (%)
Expected 
value 
(%)
20210GG 294 (97.03) 97.05 0.50 0.14 53 (94.64) 94.72 0.27 0.09 394 (98.50) 98.51
20210GA 9 (2.97) 2.93 2.01 0.14 3 (5.36) 5.21 3.72 0.09 6 (1.50) 1.49
20210AA 0 (0.00) 0.02 – – 0 (0.00) 0.07 – – 0 (0.00) 0.00
Total 303 (100.00) 100.00 56 (100.00) 400 (100.0) 100.00
Alleles
20210G 597 (98.51) – 0.50 0.14 109 (97.32) – 0.27 0.09 794 (99.25) –
20210A 9 (1.49) – 1.99 0.14 3 (2.68) – 3.72 0.09 6 (0.75) –
Total 606 (100.00) – 112 (100.00) – 800 (100.00) –
Study subgroups were compared to the control group; p — one-sided exact Fisher test
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As for the 677C>T MTHFR gene polymorphism, the oc-
currence of genotypes and alleles was similar in all analyzed 
groups. The frequency of the heterozygous 677CT genotype 
was comparable in both study subgroups and in controls 
(42.24% in the RM < 13 w.g. subgroup, 44.64% in the RM 
13–22 w.g. subgroup, 41.00% in controls, ns). In case of 
the mutated 677TT genotype, its frequency was 11.88% 
in the RM < 13 w.g. subgroup, 8.93% in the RM 13–22 w.g. 
subgroup, and 8.75% in controls, ns. A similar correlation 
was found for allele frequency (Table 7).
For the 1298A>C MTHFR gene polymorphism, the follow-
ing genotype distribution was observed: in the RM < 13 w.g. 
subgroup — 1298AA: 1298AC: 1298CC = 40.59: 47.20: 
12.21%, in the RM 13–22 w.g. subgroup — 1298AA: 1298AC: 
1298CC = 51.79: 35.71: 12,50%, in controls — 1298AA: 
1298AC: 1298CC = 44.75: 43.00: 12.25%. No statistically sig-
nificant correlations were found. The occurrence of the al-
leles was as follows: in the RM < 13 w.g. subgroup — 1298A: 
1298C = 64.19: 35.81%, in the RM 13–22 w.g. subgroup 
— 1298A: 1298C = 69.64: 30.36% in controls — 1298A: 
1298C = 66.25: 33.75% (Table 8).
A similar finding was made about the 1793G>A MTH-
FR gene polymorphism. Statistically significantly higher 
frequency of the heterozygous 1793GA genotype in the 
RM < 13 w.g. subgroup was noted (12.21 vs. 7.75% in con-
trols, OR = 1.66, p = 0.03). Also, the occurrence of genotypes 
containing the mutated 1793A allele (1793GA + 1793AA) 
was significantly higher in the RM < 13 w.g. subgroup 
(12.54 vs. 8.00% in controls, OR = 1.65, p = 0.03). A statis-
tically significant correlation was found also for the fre-
quency of the mutated 1793A allele, which was higher in the 
RM < 13 w.g. subgroup (6.44 vs. 4.13% in controls, OR = 1.60, 
Table 6. The frequency of genotypes and alleles of the 11496G>A factor VII gene polymorphism in the study group and controls
FVII
R353Q
(11496G>A)
Study group RM (n=359)
Control group (n = 400)
RM < 13 w.g. (n = 303) RM 13–22 w.g. (n = 56)
Genotypes
Observed 
value
n (%)
Expected 
value 
(%)
OR p
Observed 
value
n (%)
Expected 
value 
(%)
OR p
Observed 
value
n (%)
Expected 
value 
(%)
11496GG 234 (77.23) 78.23 1.10 0.33 49 (87.50) 86.22 2.27 0.03 302 (75.50) 75.69
11496GA 68 (22.44) 20.43 0.97 0.47 6 (10.71) 13.27 0.40 0.02 92 (23.00) 22.62
11496AA 1 (0.33) 1.34 0.22 0.12 1 (1.79) 0.51 1.19 0.60 6 (1.50) 1.69
Total 303 (100.00) 100.00 56 (100.00) 100.00 400 (100.00) 100.00
Alleles
11496G 536 (88.45) – 1.14 0.23 104 (92.86) – 1.94 0.05 696 (87.00) –
11496A 70 (11.55) – 0.87 0.23 8 (7.14) – 0.51 0.05 104 (13.00) –
Total 606 (100.00) – 112 (100.00) – 800 (100.00) –
Study subgroups were compared to the control group; p — one-sided exact Fisher test
Table 7. The frequency of genotypes and alleles of the 677C>T MTHFR gene polymorphism in in the study group and controls
MTHFR
677C>T
Study group RM (n = 359)
Control group (n = 400)
RM < 13 w.g. (n = 303) RM 13–22 w.g. (n = 56)
Genotypes
Observed 
value
n (%)
Expected 
value
(%)
OR p
Observed 
value
n (%)
Expected 
value
 (%)
OR p
Observed 
value
n (%)
Expected 
value
(%)
677CC 139 (45.88) 44.89 0.84 0.14 26 (46.43) 47.26 0.86 0.35 201 (50.25) 50.05
677CT 128 (42.24) 44.22 1.05 0.40 25 (44.64) 42.97 1.16 0.35 164 (41.00) 41.39
677TT 36 (11.88) 10.89 1.41 0.11 5 (8.93) 9.77 1.02 0.56 35 (8.75) 8.56
Total 303 (100.00) 100.00 56 (100.00) 100.00 400 (100.00) 100.00
Alleles
677C 406 (67.00) – 0.84 0.07 77 (68.75) – 0.91 0.37 566 (70.75) –
677T 200 (33.00) – 1.19 0.07 35 (31.25) – 1.10 0.37 234 (29.25) –
Total 606 (100.00) – 112 (100.00) – 800 (100.00) –
Study subgroups were compared to the control group; p — one-sided exact Fisher test
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p = 0.03), whereas there were no significant dissimilarities in 
the RM 13–22 w.g. subgroup and controls (Table 9).
DISCUSSION
The present study involved patients with RM as well as 
healthy controls. It is one of the biggest analyses concern-
ing inherited thrombophilia and RM in the Polish popula-
tion. The study group is fully representative for that kind of 
research. Owing to the sample size, the statistical tests are 
reliable. Significant differences of frequencies of genetic 
variants between diverse ethnic and regional groups have 
been reported and that is why eligibility criteria should also 
include ethnic homogeneity. In our study, all women were 
Caucasian and of Polish origin. In similar studies, comparing 
healthy and unhealthy unrelated groups of patients, ade-
quate exclusion and inclusion criteria are of vital importance. 
Inadequate eligibility criteria and insufficient sample size 
are the most common reasons of obtaining conflicting results 
concerning the frequency of genetic polymorphisms [16]. 
Noteworthy, the abovementioned study considered 7 ge-
netic polymorphisms in 4 genes of coagulation cascade, 
folate and homocysteine metabolism.
Factor V Leiden (1691G>A) is one of the most commonly 
analyzed factors involved in the etiology of RM and has been 
suggested to be the dominant cause of miscarriage in the 
first and second trimesters of pregnancy. A multi-center 
study by Skrzypczak et al., performed in 2012, investigated 
396 patients with at least one pregnancy loss (122 women 
with 3 or more early RM, 87 with late RM and 46 with 
IUFD) and 50 women with a negative history of pregnancy 
loss. Their results revealed a possible role of the factor V 
Leiden in the etiology of RM. Additionally, those authors 
emphasized the need to perform factor V Leiden screening 
tests among patients with the diagnosis of RM [17]. A study 
Table 8. The frequency of genotypes and alleles of the 1298A>C MTHFR gene polymorphism in in the study group and controls
MTHFR
1298A>C
Study group RM (n = 359)
Control group (n = 400)
RM < 13 w.g. (n = 303) RM 13–22 w.g. (n = 56)
Genotypes
Observed 
value
n (%)
Expected 
value
(%)
OR p
Observed 
value
n (%)
Expected 
value
(%)
OR p
Observed 
value
n (%)
Expected 
value
(%)
1298AA 123 (40.59) 41.21 0.84 0.15 29 (51.79) 48.50 1.33 0.20 179 (44.75) 43.89
1298AC 143 (47.20) 45.97 1.18 0.15 20 (35.71) 42.28 0.74 0.19 172 (43.00) 44.72
1298CC 37 (12.21) 12.82 0.99 0.54 7 (12.50) 9.22 1.02 0.55 49 (12.25) 11.39
Total 303 (100.00) 100.00 56 (100.00) 100.00 400 (100.00) 100.00
Alleles
1298A 389 (64.19) – 0.91 0.23 78 (69.64) – 1.17 0.27 530 (66.25) –
1298C 217 (35.81) – 1.10 0.23 34 (30.36) – 0.86 0.27 270 (33.75) –
Total 606 (100.00) – 112 (100.00) – 800 (100.00) –
Study subgroups were compared to the control group; p — one-sided exact Fisher test
Table 9. The frequency of genotypes and alleles of the 1793G>A MTHFR gene polymorphism in the study group and controls 
MTHFR
1793G>A
Study group RM (n = 359)
Control group (n = 400)
RM < 13 w.g. (n = 303) RM 13–22 w.g. (n = 56)
Genotypes
Observed 
value
n (%)
Expected 
value
(%)
OR p
Observed 
value
n (%)
Expected 
value
(%)
OR p
Observed 
value
n (%)
Expected 
value
(%)
1793GG 265 (87.46) 87.54 0.61 0.03 50 (89.29) 89.57 0.72 0.32 368 (92.00) 91.92
1793GA 37 (12.21) 12.04 1.66 0.03 6 (10.71) 10.14 1.43 0.29 31 (7.75) 7.91
1793AA 1 (0.33) 0.42 1.32 0.68 0 (0.00) 0.29 – – 1 (0.25) 0.17
Total 303 (100.00) 100.00 56 (100.00) 100.00 400 (100.00) 100.00
Alleles
1793G 567 (93.56) – 0.63 0.03 106 (94.64) – 0.76 0.34 767 (95.87) –
1793A 39 (6.44) – 1.60 0.03 6 (5.36) – 1.32 0.34 33 (4.13) –
Total 606 (100.00) – 112 (100.00) – 800 (100.00) –
Study subgroups were compared to the control group; p — one-sided exact Fisher test
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by Sergi et al., performed in 2015, concerned 9 analyses of 
the Leiden mutation and its significance in RM in the first 
trimester of pregnancy. The study involved 2147 patients 
(1305 with RM and 842 healthy women). Higher frequency 
of factor V Leiden was observed in the study group. These 
authors voiced the need to investigate the presence of fac- 
tor V Leiden in each woman with RM of an unknown origin. 
Moreover, they recommended antithrombotic prophylaxis in 
all patients with RM and the presence of factor V Leiden [18]. 
On the other hand, there are also some studies which do 
not confirm correlation of factor V Leiden with increased 
risk for RM, which is consistent with our findings. Bauman et 
al., performed a multi-center analysis of the frequency of 
factor V Leiden, prothrombin mutation and 677C>T MTHFR 
polymorphism in a group of 641 patients (240 with 2 RM 
and 401 with 3 or more RM) and 157 healthy controls. All 
women were Caucasian. No statistically significant differ-
ences between the analyzed groups were found [19]. 
Relatively few studies have dealt with the 1328T>C 
factor V gene polymorphism. An interesting analysis was 
performed in the Polish population. The study group in-
cluded 136 patients with 2 or more RM and 106 controls. The 
1691G>A and 1328T>C polymorphisms were evaluated in all 
subjects. Heterozygous 1328TC genotype was more frequent 
in women with RM before 7 w.g. These authors recommend 
1328T>C factor V gene polymorphism screening in women 
with a positive history of RM [20].
An analysis of the correlations of the 20210G>A pro-
thrombin gene polymorphism has been already performed 
in the Polish population. In the study of Barlik et al., 
20210G>A and 19911A>G prothrombin gene polymor-
phisms were evaluated in a group of 150 women with 2 or 
more RM and 180 controls. An overrepresentation of the 
20210GA genotype (2.7% vs. 1.1% in controls, OR = 2.44, ns) 
and the 20210A allele (1.3% vs. 0.6% in controls, OR = 2.42, 
ns) was observed in the RM group. These authors sug-
gested a possible role of the 20210G>A prothrombin gene 
polymorphism in the etiology of RM [21]. Special attention 
should be paid to the meta-analysis of Gao et al., involving 
37 studies, including 5400 women with 2 or more RM and 
4640 controls. It revealed a correlation of the 20210G>A poly-
morphism with increased risk for pregnancy loss among the 
European population and women over 29 years of age [22].
The decision to evaluate the R353Q (11496G>A) factor VII 
polymorphism in the etiology of RM was inspired by reports 
from the field of cardiology. Factor VII plasma concentra-
tion and activity are potential risk factors for thrombotic 
changes. In carriers of the mutated Gln353 allele factor VII, 
plasma concentration and activity are decreased, leading 
to lower risk of thrombotic events [23]. Moreover, a study 
by Seremak-Mrozikiewicz et al., including 104 women with 
RM between 6-13 w.g. and 163 controls, revealed a protec-
tive role of the Gln353 allele as far as the occurrence of RM 
was concerned [24], which is consistent with our findings.
A considerable amount of research has focused on the 
possible role of 667C>T, 1298A>C, 1793G>A polymorphisms 
of the MTHFR gene in the etiology of RM. One study in the 
Polish population (104 women with RM and 169 controls) 
has been already performed. Higher frequency of the hetero- 
zygous 1793GA genotype in the RM group was noted 
(15.38% vs. 4.14% in controls, OR = 4.21, p = 0.003). There 
were no statistical differences regarding the 667C>T and 
1298A>C genetic variants [25].
A meta-analysis performed in 2006 by Robertson 
et al., is a very comprehensive research which involved 
25 studies on miscarriage in the early pregnancy, RM in 
the first trimester of pregnancy, and late abortions. The 
role of the 1691G>A factor V gene polymorphism and the 
20210G>A factor II gene polymorphism in the etiology of 
RM in the first trimester and late abortions was identified. 
Also, much attention was paid to the meaning of acquired 
hyperhomocysteinemia in the increased risk for RM. Interest-
ingly, a correlation between anticardiolipin antibodies and 
RM in the first trimester of pregnancy and late abortions 
was reported [26].
CONCLUSIONS
1. A significantly higher frequency of the mutated vari-
ants of the 1793G>A polymorphism of the MTHFR gene 
in the RM < 13 w.g. subgroup indicates the role of this 
polymorphism in the etiology of early miscarriage. 
2. A role of the wild-type 353RR (11496GG) genotype and 
wild-type 353R (11496G) allele of the R353Q (11496G>A) 
factor VII gene polymorphism in the etiology of late 
miscarriages (RM between 13–22 w.g.) was revealed.
3. The observed overrepresentation of the mutated geno-
type and allele of the 20210G>A factor II gene polymor-
phism in the entire study group may suggest a possible 
role of these variants in the etiology of RM.
4. Statistically significant correlations are consistent with 
reports of other authors, which further emphasizes the 
value of our findings.
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